Tempus AI and Whitehawk Therapeutics Partner on AI-Driven Cancer Research
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.
Shares of Tempus AI rose following the executive order promoting the use of AI to develop solutions for pediatric cancer.
Tempus AI's FDA-cleared Pixel update uses AI to analyze heart MRI scans, generating detailed tissue maps to detect hidden issues like fibrosis, helping doctors provide more precise, personalized care.